Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Genetic variability within the SLCO1B1 and ABCB1 transporter genes has been associated with modification of statin effectiveness in cholesterol management.We conducted a case-control study using a population-based registry of pharmacy records linked to the hospital discharge records. Within a hypercholesterolemic cohort, we included 668 myocardial infarction cases and 1217 controls.We tested 24 tagging SNPs and found two SNPs within ABCB1 (rs3789244, p = 0.01; rs1922242, p = 0.01) to interact with statin treatment. In addition, we found a nonsignificant haplotype-treatment interaction (p = 0.054). The odds ratio for subjects homozygous for SLCO1B1*1A was 0.49 (95% CI: 0.34-0.71) compared with 0.31 (95% CI: 0.24-0.41) for heterozygous or noncarriers of the *1A allele.This is the first study to demonstrate that common genetic variability within the SLCO1B1 and ABCB1 genes is associated with the modification of the effectiveness of statins in the prevention of the clinical outcome, myocardial infarction.

Original publication

DOI

10.2217/pgs.10.81

Type

Journal article

Journal

Pharmacogenomics

Publication Date

08/2010

Volume

11

Pages

1065 - 1076

Addresses

Faculty of Science, Division of Pharmacoepidemiology & Pharmacotherapy, Utrecht University, Utrecht, The Netherlands.

Keywords

Humans, Myocardial Infarction, P-Glycoproteins, P-Glycoprotein, Organic Anion Transporters, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Treatment Outcome, Medical Records, Incidence, Logistic Models, Case-Control Studies, Pharmacogenetics, Haplotypes, Polymorphism, Single Nucleotide, Middle Aged, Female, Male, Solute Carrier Organic Anion Transporter Family Member 1b1